1.	Phase III Randomized Study of Induction Therapy Comprising Daunorubicin Hydrochloride and Cytarabine With or Without Midostaurin Followed by Consolidation Therapy Comprising High-Dose Cytarabine and Midostaurin Followed by Continuation Therapy Comprising Midostaurin Alone in Patients With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Closed Age: 18 to 59 Sponsor: NCI Protocol IDs: CALGB-10603, CALGB 10603, EUDRACT-2006-006852-37, NCT00651261
2.	Phase I/II Study of PKC412 With or Without Itraconazole in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-02021, NOVARTIS-CPKC412A2104, NCI-G02-2107, UCLA-0305058-01, NCT00045578
3.	Phase II PKC412 in Aggressive Systemic Mastocytosis and Mast Cell Leukemia Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: HEMMPD0003, 95242, Novartis 2213, NCT00233454
4.	Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia Phase: Phase II Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: CPKC412D2201, 2008-000280-42, NCT00782067
5.	Phase I Study of PKC412 Administered Sequentially or Concurrently With Induction Chemotherapy Comprising Daunorubicin and Cytarabine Followed By Consolidation Therapy Comprising High-Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia Phase: Phase I Type: Treatment Status: Closed Age: 18 to 60 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0308139-01, NOVARTIS-CPKC412A2106, NCT00093600
6.	RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 08-269, NCT00819546
7.	Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Phase: No phase specified Type: Behavioral study, Natural history/Epidemiology, Treatment Status: Completed Age: 60 and older Sponsor: Other Protocol IDs: 2004-0060, NCT00459524